KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Equity Average (2016 - 2025)

AbbVie (ABBV) has disclosed Equity Average for 13 consecutive years, with $2.4 billion as the latest value for Q1 2025.

  • On a quarterly basis, Equity Average fell 74.05% to $2.4 billion in Q1 2025 year-over-year; TTM through Mar 2025 was $2.4 billion, a 74.05% decrease, with the full-year FY2024 number at $6.9 billion, down 50.43% from a year prior.
  • Equity Average was $2.4 billion for Q1 2025 at AbbVie, down from $4.7 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $16.7 billion in Q4 2022 to a low of $2.4 billion in Q1 2025.
  • A 5-year average of $11.8 billion and a median of $13.1 billion in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 272.13% in 2021, then tumbled 74.05% in 2025.
  • AbbVie's Equity Average stood at $14.5 billion in 2021, then grew by 14.82% to $16.7 billion in 2022, then crashed by 32.38% to $11.3 billion in 2023, then crashed by 58.29% to $4.7 billion in 2024, then crashed by 49.05% to $2.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Equity Average are $2.4 billion (Q1 2025), $4.7 billion (Q4 2024), and $6.4 billion (Q3 2024).